StockNews.com Initiates Coverage on Alimera Sciences (NASDAQ:ALIM)

StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research report issued on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on ALIM. Maxim Group reissued a “hold” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. Alliance Global Partners reissued a “neutral” rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. Finally, HC Wainwright cut shares of Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 price target for the company. in a research report on Tuesday, June 25th.

Alimera Sciences Price Performance

ALIM opened at $5.52 on Thursday. Alimera Sciences has a 12 month low of $2.60 and a 12 month high of $5.65. The business has a 50-day moving average of $3.60 and a two-hundred day moving average of $3.73. The company has a debt-to-equity ratio of 1.71, a current ratio of 2.62 and a quick ratio of 2.51. The stock has a market capitalization of $289.19 million, a price-to-earnings ratio of -3.52 and a beta of 1.27.

Alimera Sciences (NASDAQ:ALIM) last released its earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The company had revenue of $23.01 million during the quarter, compared to analyst estimates of $23.72 million. Alimera Sciences had a negative return on equity of 53.49% and a negative net margin of 23.74%. During the same period in the prior year, the business posted ($0.71) earnings per share. On average, research analysts expect that Alimera Sciences will post -0.13 earnings per share for the current year.

Institutional Trading of Alimera Sciences

Several large investors have recently bought and sold shares of the company. Fifth Lane Capital LP acquired a new position in shares of Alimera Sciences during the first quarter worth $83,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Alimera Sciences during the first quarter worth approximately $169,000. Ancora Advisors LLC acquired a new position in Alimera Sciences during the 1st quarter worth $915,000. Vanguard Group Inc. grew its stake in Alimera Sciences by 61.1% in the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock worth $4,077,000 after purchasing an additional 396,506 shares in the last quarter. Finally, Stonepine Capital Management LLC increased its holdings in shares of Alimera Sciences by 0.4% in the 4th quarter. Stonepine Capital Management LLC now owns 3,999,459 shares of the biopharmaceutical company’s stock valued at $17,278,000 after acquiring an additional 15,773 shares during the last quarter. Institutional investors and hedge funds own 99.83% of the company’s stock.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).